Finance

Lists
RGNX:NASDAQ
Regenxbio Inc
$7.43
+0.13%
(+0.0100) 1D
$7.48
+0.67% (+0.050)
After hours
Closed: Oct 2, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RGNX...
Open
$7.58
High
$7.62
Low
$7.36
Mkt. cap
490.48M
Avg. vol.
1.49M
Volume
1.04M
52-wk high
$16.19
52-wk low
$5.46
EPS
-$3.79
Beta
1.13
Shares outstanding
66.01M
No. of employees
371
Open
$7.58
High
$7.62
Low
$7.36
Mkt. cap
490.48M
Avg. vol.
1.49M
Volume
1.04M
52-wk high
$16.19
52-wk low
$5.46
EPS
-$3.79
Beta
1.13
Shares outstanding
66.01M
No. of employees
371
News stories
From web sources and news partners
About Regenxbio Inc
CEO-
Employees371
Founded2008
HeadquartersRockville, Maryland, United States
SectorBiotechnology
Websiteregenxbio.com
Analyst ratings
Based on 9 analysts giving stock ratings to RGNX in the past 3 months
Strong buy
Buy
7
Hold
2
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for RGNX in the last 3 months.
Highest
Current $7.43
$42.00 (+465.28%)
Average
$22.00 (+196.10%)
Lowest
$10.00 (+34.59%)
Analyst
Recommendation
Action
Price target
Projected
Date
Annabel Samimy
Stifel Nicolaus
Buy
Reiterated
$42.00
+465.3%
09/25/2026
Yi Chen
H.C. Wainwright
Buy
Reiterated
$21.00
+182.6%
09/25/2026
Alec Stranahan
Bank of America Securities
Buy
Reiterated
$15.00
+101.9%
09/21/2026
Paul Choi
Goldman Sachs
Hold
Maintained
$10.00
+34.6%
08/24/2026
Judah Frommer
Morgan Stanley
Buy
Maintained
$18.00
+142.3%
08/24/2026
Brian Skorney
Robert W. Baird
Buy
Maintained
$29.00
+290.3%
08/25/2026
Mara Goldstein
Clear Street
Buy
Maintained
$32.00
+330.7%
08/25/2026
William Maughan
Clear Street
Buy
Maintained
$32.00
+330.7%
08/24/2026
Luca Issi
RBC Capital
Buy
Maintained
$19.00
+155.7%
08/06/2026
Eliana Merle
Barclays
Hold
Downgraded
$12.00
+61.5%
08/07/2026
Mani Foroohar
Leerink Partners
Buy
Maintained
$17.00
+128.8%
05/15/2026
Daniil Gataulin
Chardan Capital
Buy
Reiterated
$52.00
+599.9%
01/28/2026
Last report
Aug 6, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$0.43 / -$0.11
+499.22%beat
Revenue / Est. (USD)
108.02M / 96.46M
+11.99%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
29.73M
30.34M
6.39M
108.02M
Cost of goods sold
61.83M
65.54M
68.41M
57.13M
Cost of revenue
61.83M
65.54M
68.41M
57.13M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
20.25M
22.38M
21.31M
21.62M
Operating expense
20.32M
22.43M
21.34M
21.63M
Total operating expenses
82.14M
87.97M
89.76M
78.76M
Operating income
-52.41M
-57.64M
-83.36M
29.26M
Other non operating income
-
-
-
-
EBT including unusual items
-61.94M
-67.15M
-90.05M
22.71M
EBT excluding unusual items
-61.94M
-67.15M
-90.05M
22.71M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
65.00K
54.00K
36.00K
12.00K
Net income
-61.94M
-67.15M
-90.05M
22.71M
Net profit margin
-208.32%
-221.34%
-1,408.59%
21.02%
Earnings per share
-1.20
-1.30
-1.72
0.43
Interest and investment income
3.64M
2.76M
2.02M
1.24M
Interest expense
-13.17M
-12.28M
-8.71M
-7.79M
Net interest expenses
-9.53M
-9.51M
-6.69M
-6.55M
Depreciation and amortization charges
-
-
-
-
EBITDA
-48.52M
-53.77M
-79.50M
33.02M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps